These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 3465383)

  • 1. Serum CA 15.3 levels in patients with general pathology and malignant diseases (excluding breast cancer).
    Ruibal A; Encabo G; Genollá J; Guarga A; Urrutia A; Colomer R
    Bull Cancer; 1986; 73(1):94-5. PubMed ID: 3465383
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical evaluation of a cancer antigen, CA 15-3, associated with breast cancer. (I) Modification of its method and reference values].
    Sakurabayashi I; Kawai T; Kawaguchi R; Yonezawa M
    Rinsho Byori; 1986 Jan; 34(1):53-8. PubMed ID: 3457966
    [No Abstract]   [Full Text] [Related]  

  • 3. [Serial changes in serum CA 19-9 levels in pancreatic cancer].
    Saito K; Tajiri H; Yoshimori M; Hijikata A; Ohkura H; Nakamura K; Ozaki H
    Gan No Rinsho; 1987 Aug; 33(9):1057-60. PubMed ID: 3476762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
    Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
    Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum CA 1,25 in patients with non-ovarian tumors. Evidence of a relation between the increase of the antigen and hepatic disease].
    Ruibal A; Siurana R; Encabo G; Cuartero A
    Med Clin (Barc); 1985 Mar; 84(9):376-7. PubMed ID: 3857424
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical evaluation of a cancer antigen, CA 125, associated with ovarian cancer. I. Technical investigation and the reference value].
    Sakurabayashi I; Kawai T; Suzuki M; Tamada T; Sato K; Yonezawa M
    Rinsho Byori; 1984 Dec; 32(12):1345-9. PubMed ID: 6597875
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with the tumor marker Ca 19-9 in an unselected group of more than 300 tumor patients.
    Souchon R; Koppenhagen K; Souchon MF; Matthes M; Boese-Landgraf J; Fitzner R; Baer U
    Cancer Detect Prev; 1985; 8(1-2):101-9. PubMed ID: 3864534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of CA 15-3 radioimmunoassay].
    Takemori Y; Odani H; Watanabe H; Ohta H; Satomura Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):114-8. PubMed ID: 3467654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum levels of the CA-125 antigen in the diagnosis of ovarian neoplasms].
    Sopracordevole F; Finco B; Scarabelli C; Campagnutta E; Alimena C; Perin A
    Minerva Ginecol; 1985 Oct; 37(10):589-96. PubMed ID: 3866146
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Basic studies and the reference values of cancer associated antigen CA-50].
    Yoshioka H; Shitara M; Sakurabayashi I; Kawai T; Suzuki M
    Rinsho Byori; 1988 Feb; 36(2):171-6. PubMed ID: 3288785
    [No Abstract]   [Full Text] [Related]  

  • 13. Seric CA 19.9 levels in patients with non tumoral pathologies. Our experience in 892 cases.
    Encabo G; Ruibal A
    Bull Cancer; 1986; 73(3):256-9. PubMed ID: 3463370
    [No Abstract]   [Full Text] [Related]  

  • 14. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
    Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
    Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CA 19-9 and CA 50 antigens in hemodialysis patients.
    Docci D; Pistocchi E; Turci F; Baldrati L; Urbini S; Scaioli S
    Clin Nephrol; 1987 Apr; 27(4):179-81. PubMed ID: 3472698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum CA 15.3 in women with non-tumor breast pathologies. Initial results].
    Ruibal A; Colomer R; Gris JM; Genollá J
    Med Clin (Barc); 1986 Sep; 87(9):393-4. PubMed ID: 3467152
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
    Crombach G; Zippel HH; Würz H
    Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
    Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
    Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CA 19-9 enzyme immunoassay].
    Ota H; Odani H; Watanabe H; Satomura Y; Takemori Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
    Gan No Rinsho; 1986 Aug; 32(9):993-7. PubMed ID: 3528560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tumor markers in the diagnosis of tumors in the subhepatic area].
    Dufek V; Petrtýl J; Klener P; Chmel J
    Vnitr Lek; 1994 Jun; 40(6):350-3. PubMed ID: 8073643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.